Article Text
PDF
Abstract
Please confirm that an ethics committee approval has been applied for or granted: Yes: I’m uploading the Ethics Committee Approval as a PDF file with this abstract submission
Background and Aims Osteoarthritis (OA) is a chronic degenerative joint disease. In recent years, adipose-derived mesenchymal stem cells (AD-MSCs) have emerged as a promising treatment for regenerative medicine. The application of stem cells to degenerated joints has been shown to restore articular cartilage, alleviate pain, and improve quality of life.
Methods This study retrospectively reviewed 86 patients with knee and hip osteoarthritis who underwent intra-articular stem cell therapy. Patients were evaluated using visual analog scale (VAS), Western Ontario and McMaster University Osteoarthritis Index (WOMAC), Lequesne, Short Form-36 (SF-36) scores, and radiological scores on current radiographs before and after the procedure. Additionally, adverse events were monitored during the 6-month follow-up period.
Results The patients’ VAS scores decreased significantly from 8 at baseline to 3 and 2 at 1st and 6th months, respectively, according to the Friedman test (p < 0.001). WOMAC total score was 65, 24 in the 1st month after treatment and 18 in the 6th month after treatment. Lequesne and SF-36 scores also improved significantly from baseline to 1st and 6th months. These measurements were statistically significant (p<0.001). No adverse events were reported. Mild transient pain and swelling were noted in a few patients in the small patient group, but no major side effects occurred.
Conclusions The intra-articular application significantly improved outcomes in patients and did not cause any side effects, suggesting that intra-articular stem cell application may be a promising option in the treatment of osteoarthritis. However, prospective RCTs with larger sample size and long-term follow-up are needed.
Obtaining abdominal adipose tissue with liposuction
Intra-articular AD-MSC application on the knee
VAS Values